NASDAQ:EDSA - Edesa Biotech Stock Price, Forecast & News

Edesa Biotech trades on the NASDAQ under the ticker symbol "EDSA."

Edesa Biotech (NASDAQ:EDSA) released its quarterly earnings data on Thursday, December, 12th. The company reported ($0.07) earnings per share for the quarter. The firm earned $0.41 million during the quarter. Edesa Biotech had a negative net margin of 784.77% and a negative return on equity of 80.11%. View Edesa Biotech's Earnings History.

Edesa Biotech is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for Edesa Biotech.

News headlines about EDSA stock have been trending very negative on Monday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Edesa Biotech earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Edesa Biotech.

Edesa Biotech saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 23,200 shares, an increase of 28.2% from the December 31st total of 18,100 shares. Based on an average trading volume of 38,100 shares, the short-interest ratio is presently 0.6 days. Currently, 0.8% of the company's shares are short sold. View Edesa Biotech's Current Options Chain.

Some companies that are related to Edesa Biotech include ProMetic Life Sciences (PFSCF), Menlo Therapeutics (MNLO), Cyclerion Therapeutics (CYCN), Xeris Pharmaceuticals (XERS), TapImmune (MRKR), Helix Biopharma (HBPCF), AcelRx Pharmaceuticals (ACRX), CymaBay Therapeutics (CBAY), Millendo Therapeutics (MLND), Corvus Pharmaceuticals (CRVS), Paratek Pharmaceuticals (PRTK), Clearside Biomedical (CLSD), Inflarx (IFRX), CannTrust (CTST) and Trillium Therapeutics (TRIL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Edesa Biotech investors own include Agile Therapeutics (AGRX), Nabriva Therapeutics (NBRV), Armata Pharmaceuticals (ARMP), vTv Therapeutics (VTVT), Vaxart (VXRT), Aduro BioTech (ADRO), Aethlon Medical (AEMD), Advanced Micro Devices (AMD), Aytu Bioscience (AYTU) and Senseonics (SENS).

Edesa Biotech's stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.33%). Company insiders that own Edesa Biotech stock include Der Velden Peter Van, Frank R Oakes and Michael J Brooks. View Institutional Ownership Trends for Edesa Biotech.

EDSA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Edesa Biotech stock in the last two years include Der Velden Peter Van and Michael J Brooks. View Insider Buying and Selling for Edesa Biotech.

Shares of EDSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EDSA stock can currently be purchased for approximately $3.60.

Edesa Biotech has a market capitalization of $31.90 million and generates $210,000.00 in revenue each year. Edesa Biotech employs 6 workers across the globe.View Additional Information About Edesa Biotech.

The official website for Edesa Biotech is http://www.edesabiotech.com/.

Edesa Biotech's mailing address is 100 SPY COURT, MARKHAM A6, L3R 5H6. The company can be reached via phone at 905-475-1234 or via email at [email protected]